Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Aimee L. Jackson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter S. Linsley(Rosetta Stone (United States))
Cited by 785
Related Papers
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.
|Proceedings of the National Academy of Sciences|1992|540
Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells.
|The Journal of Immunology|1994|374